AI enabled Precision Treatment for Chronic Metabolic Diseases

Chronic metabolic diseases, such as type 2 diabetes, prediabetes, obesity, fatty liver, and dyslipidemia, often originate as an individual's metabolism gradually breaks down. Medical research reveals the unique functioning of each person's metabolism, posing challenges for healthcare providers in understanding and customizing personalized treatments. Addressing this complexity, a digital healthcare entity utilizes cutting-edge technology and advanced medical science to deliver personalized, precise, and timely insights with easy-to-follow recommendations to address the root cause.

Through an intuitive app, the AI-enabled Precision Treatment Technology provides members and the clinical care team individualized, precise, and timely guidance across medicine, nutrition, sleep, activity, and stress.

The Precision Treatment Platform serves as a dynamic model of each individual's unique metabolism, powered by artificial intelligence (AI) built from thousands of data points collected daily via wearable sensors, clinical lab parameters, and self-reported preferences. This platform offers thousands of parameters in a single dashboard to assist health coaches and doctors in deciding quickly. Clinical trials showed that the AI-enabled Platform assist not only to reverse type 2 diabetes but also improves the condition of dyslipidemia, hypertension, obesity, fatty liver, pancreas B cell dysfunction, inflammation and mental health of the patient.  

In Bangladesh, approximately 13 million individuals are affected by Type 2 diabetes, with a prevalence rate of 12.5%, and an additional estimated 6 million patients remain undiagnosed. Chronic metabolic disease is a growing concern globally, with the worldwide prevalence of Metabolic Syndrome estimated at 20-25%. According to the Center of Disease Control and Prevention (CDC), 415 million people globally are living with type 2 diabetes, a number projected to surpass 500 million by 2040.

The AI-enabled treatment platform has impacted over 4 million lives. Noteworthy achievements include completing the world's first randomized controlled trial (RCT) for reversing chronic metabolic disease using digital twin technology. Recently published in the American Association of Clinical Endocrinology, the one-year results showed a significant reduction in HbA1c in the intervention group (2.9% reduction from 9.0 to 6.1) and a significantly higher elimination of diabetes medications (94% elimination of type 2 diabetes medications in the intervention group). The study demonstrated an average weight loss of 7.4 kg, and 64% of members witnessed a normalization of their baseline non-alcoholic fatty liver disease (NAFLD). The RCT continues into its 3rd year with sustained health outcomes.

Today, a large and growing number of people around the world are suffering from chronic metabolic diseases, including type-2 diabetes, pre-diabetes, and obesity. The Precision Treatment Platform’s innovative approach combines advanced technology, machine learning, and compassionate care to change the lives of these individuals. It empowers people to take control of their health and reverse metabolic diseases, including type-2 diabetes. The AI-enabled digital platform is delivering on its promise of happier and healthier people, offering significant cost savings to households and employer healthcare plans.

Author: Dr. Shahjada Selim, MBBS, MD (Endocrinology), MACE (USA). Currently serving as an Associate Professor in Endocrinology at Bangabandhu Sheikh Mujib Medical University Hospital, Dr. Selim specializes in Diabetes, Thyroid Disorders, Obesity, Metabolic Disorders, and Sexual Dysfunctions.